Below you will find more information about Acyl-CoA dehydrogenase, very short chain, deficiency of from Medigest. If you believe that you are suffering from any of the symptoms of Acyl-CoA dehydrogenase, very short chain, deficiency of it is important that you obtain an accurate diagnosis from a medical professional to ensure that you obtain the correct medication or treatment for your condition. There are medical conditions that carry similar symptoms associated with Acyl-CoA dehydrogenase, very short chain, deficiency of and therefore the information provided by Medigest is offered as a guideline only and should never be used in preference to seeking professional medical advice. The information relating to Acyl-CoA dehydrogenase, very short chain, deficiency of comes from a third party source and Medigest will not be held liable for any inaccuracies relating to the information shown.
Short Chain Acyl-CoA Dehydrogenase Deficiency (SCADD) is a condition in which the body fails to oxidize fatty acids because an enzyme is either missing or not functioning correctly. Short-chain acyl-coenzyme A (CoA) dehydrogenase deficiency (SCAD) is a rare condition that stops the body from converting certain fats into energy, especially during periods without food (fasting). People affected with this disorder are not able to break down a certain group of fats called short-chain fatty acids efficiently. Some affected infants will display vomiting, low blood sugar (hypoglycemia), a lack of energy (lethargy), poor feeding, and failure to gain weight and grow at the expected rate (failure to thrive). Other features of this disorder may include poor muscle tone (hypotonia), developmental delays, seizures, and a small head size (microcephaly). The symptoms of short-chain acyl-CoA dehydrogenase deficiency may be activated by periods of fasting or during illnesses such as viral infections. In some cases, signs and symptoms may not exhibit themselves until adulthood, when some individuals may develop muscle weakness and wasting. Other people with gene mutations that can lead to this disorder may have such mild symptoms that they are never diagnosed.
This disorder is thought to affect an estimated 1 in 40,000 to 100,000 newborns. The gene defect for SCADD is a genetic trait that is autosomal recessive and is unknowingly passed down from generation to generation. This faulty gene only arises when two carriers have children together and pass it to their offspring. For each pregnancy of two such carriers, there is a 25% probability that the child will be born with the disease and a 50% chance the child will be a carrier for the gene defect.
Treatment of SCADD typically consists of avoidance of fasting (by frequent meals) and use of glucose IV required when food cannot be tolerated (such as with a virus, cold, flu, etc.). Intake of short-chain fatty acids is best avoided. Supplemental carnitine is recommended for some children affected with SCADD. Fundamental to the medical management of SCAD deficiency is to avoid fasting, especially during periods of high metabolic stress, such as illness. Overnight fasts should be managed with nighttime or late evening feedings where necessary. The addition of food-grade uncooked cornstarch mixed in liquid for a bedtime feeding has aided in decreasing the frequency of morning hypoglycemic episodes in several patients. High carbohydrate intake should be encouraged during illness, with initiation of intravenous glucose supplementation if the child has failed to keep down fluids, or unable to take adequate oral feedings.
Symptoms and Signs
Symptoms of SCADD are the inability to thrive and hypoglycemia. Over time without proper treatment, development may be delayed.Discuss Acyl-CoA dehydrogenase, very short chain, deficiency of in our forums
Discuss Acyl-CoA dehydrogenase, very short chain, deficiency of with other members of Medigest in our forums.